继5月在美国临床肿瘤学会（ASCO）年会公布并于8月26日获得美国药品监管机构加速批准的胰腺癌新疗法之后，8月19日公布的一项临床中期试验结果表明，利用mRNA技术定制的个性化疫苗能够有效抵御黑色素瘤复发。尽管过去数十年投入数十亿美元的传统癌症疫苗因单抗原逃逸及肿瘤微环境的免疫抑制而屡屡受挫，但能够解除免疫刹车的“免疫检查点抑制剂”的问世，为联合疫苗疗法开辟了全新路径。

由美国莫德纳（Moderna）与默沙东（Merck）联合研发的个性化mRNA疫苗intismeran，能够在数周内针对患者肿瘤特有的突变蛋白（新抗原）完成快速合成。在针对完成手术切除的黑色素瘤患者开展的多年联合临床试验中，中期数据显示该疫苗联合检查点抑制剂显著延缓了肿瘤复发。不过，延缓复发是否能转化为总生存期的实质性延长尚存不确定性，且治疗成本与实际疗效量级仍待全面评估；加之黑色素瘤本身具有极强的免疫原性，其积极结果能否复制至其他恶性肿瘤仍需验证。

即便如此，肿瘤临床专家仍将此视为癌症防治的重要突破，因其确立了通过强化自身免疫系统追杀微小残留病灶、遏制术后复发的有效范式。这一机制有望显著降低患者对化疗和放疗等高毒性传统疗法的依赖。目前，两家制药巨头正全速推进针对肺癌、膀胱癌和肾癌的临床试验，未来数年内公布的完整临床数据将最终确证mRNA个性化疫苗是否真正引发肿瘤治疗范式的根本性革命。

Following the August 26th accelerated regulatory approval in America of a pancreatic cancer therapy unveiled at the ASCO meeting in May, interim clinical trial data released on August 19th demonstrate that personalized mRNA technology can effectively vaccinate patients against their own melanoma. Although cancer vaccines historically absorbed billions of dollars with minimal clinical success due to single-antigen shedding and tumor-mediated immune suppression, combining vaccines with checkpoint inhibitors that disable tumor defense mechanisms has fundamentally revitalized the oncology field.

Developed collaboratively by Moderna and Merck, the personalized mRNA vaccine intismeran manufactures tailor-made treatments targeting unique patient neoantigens within weeks. Multi-year trial data evaluating intismeran alongside a checkpoint inhibitor in melanoma patients following surgical resection confirm that the vaccine significantly delays disease recurrence. Crucial caveats remain: delayed recurrence may not guarantee improved overall survival, the magnitude of the clinical response relative to high treatment costs remains unquantified, and melanoma’s exceptional immunogenicity might not generalize easily to less responsive solid tumors.

Nevertheless, oncologists view the findings as a breakthrough in post-surgical cancer management, providing a viable pathway to eliminate microscopic residual tumor clusters that typically drive lethal relapses. Successful vaccination could also reduce patient exposure to cytotoxic radiation and chemotherapy. With Moderna and Merck aggressively accelerating clinical trials across lung, bladder, and kidney malignancies, forthcoming comprehensive data will determine whether mRNA cancer vaccines represent a permanent paradigm shift across broader oncology.

Source: It now seems possible to vaccinate against cancer

Subtitle: The latest results are promising, but not yet definitive

Dateline: Aug 27th 2026